ArticleJournal of clinical laboratory analysis2026
Association Between Multi-Laboratory Parameters Pre- and Post-Treatment and Pathological Features and Their Values in Clinical Decision in Primary Hepatic Carcinoma.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary hepatic cancer (PHC) is still a significant burden worldwide. The efficacy of diagnosis, treatment response monitoring, and prognostication using laboratory biomarkers is still a challenge. This study analyzed multi-laboratory parameters pre- and post-treatment and their associations with clinical and pathological features and clinical decisions in PHC patients to evaluate their clinical usefulness.
methodsThis study analyzed laboratory data from PHC patients by comparing changes between pre- and post-treatment and the efficacy of commonly used tumor markers and their associations with clinical and pathological features. Data from 441 PHC patients were analyzed.
resultsSerum alpha-fetoprotein (AFP) and alpha-L-fucosidase (AFU), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (γ-GT), indirect bilirubin (IBIL), and hepatitis B virus DNA (HBV DNA) were reduced after treatment; AFP, carcinoembryonic antigen (CEA), and cancer antigen 19-9 (CA-199) showed value in assisting the judgment of surgical resection; serum ferritin increased significantly along with stage advanced. AFP, CEA, CA-199, and ferritin were lower in surgical resection patients than non-surgical patients. A significant association was displayed between AFP levels and multiple biomarkers and clinical features when AFP cut-off was adjusted to 140 ng/mL. AFP was increased in PHC patients with chronic hepatitis B infection and liver cirrhosis, while CA-199 was decreased in both situations.
conclusionsTumor marker AFP, CEA, CA-199, serum chemistry test panel AFU, ALT, AST, γ-GT, bilirubin, protein, and HBV DNA are useful indicators in monitoring therapeutic response and disease progression and may be used as indicators in assisting the judgment of surgical resection of PHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.